How much does a box of Olaparib cost?

Olaparib (Olaparib), as an advanced targeted therapy drug, mainly targets cancer patients carrying BRCA1 or BRCA2 gene mutations. It has shown significant efficacy in the treatment of ovarian cancer, breast cancer, pancreatic cancer and prostate cancer. These gene mutations can interfere with the normal repair mechanism of DNA, causing cells to gradually accumulate genetic damage, which may lead to cancer. Olaparib exerts its therapeutic effect by acting on the PARP (polyADP-ribose polymerase) protein in cancer cells, a key player in DNA repair.

Currently, olaparib has been launched in the domestic market and has been successfully included in the medical insurance system, providing patients with purchasing convenience. The specification and price of its 150 mg 56 tablets ranges from four to five thousand yuan. For specific costs and medical insurance reimbursement details, patients are advised to consult the local hospital pharmacy for accurate information. In foreign countries, especially in places such as Bangladesh and Laos, the price of generic drugs is more affordable. The price of 150mg120 tablets is only about 2,000 yuan, and the drug ingredients are basically the same as the original drugs, providing patients with more choices.

PARPis expressed in both normal and cancer cells, but its position is particularly critical in cells with BRCA gene mutations. When the BRCA gene is damaged, cells become more dependent on PARP because they lack other pathways to repair DNA double-strand breaks. By inhibiting PARP, olaparib further weakens the self-repair ability of these cancer cells, leading to DNA irreparable damage and ultimately triggering cell apoptosis. This "synthetic lethality" mechanism selectively eliminates tumor cells by blocking the repair pathways of cancer cells, while having little effect on normal cells.

Since being approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced ovarian cancer in 2014, olaparib's indications have continued to expand and now cover a variety of cancer types. At the same time, the study also revealed that olaparib is not limited toBRCA mutation patients may also have positive effects on patients carrying other specific DNA repair gene defects.